Notice2023-10485
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 17, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 95 (Wednesday, May 17, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 95 (Wednesday, May 17, 2023)]
[Notices]
[Page 31511]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-10485]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852 by contacting Dr. Benjamin Hurley at
240-669-5092 or <a href="/cdn-cgi/l/email-protection#c6a4a3a8aca7abafa8e8aeb3b4aaa3bf86a8afaee8a1a9b0"><span class="__cf_email__" data-cfemail="7a181f14101b17131454120f08161f033a141312541d150c">[email protected]</span></a>. A signed Confidential
Disclosure Agreement will be required to receive copies of unpublished
information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Nanoparticle Vaccine Against Mpox
Description of Technology:
In 2022, the World Health Organization declared an atypical
outbreak of monkeypox (Mpox), which has caused approximately 30,000
cases of Mpox infection within the United States as of April 2023. Mpox
represents a current threat to public health, and there is an immediate
need for an effective vaccine. To address this, NIAID has developed a
vaccine approach comprising virus-like nanoparticles coated with
modified Mpox proteins. NIAID investigations have demonstrated that
immunization has elicited a robust immune response in mice and provided
protection against a lethal infection of Vaccinia virus.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Immunization: Mpox nanoparticle vaccines may be more
effective than current MVA vaccination approaches in providing
protection against Mpox infection.
<bullet> The methodology for manufacturing the Mpox nanoparticle
vaccine could be readily adapted to generate vaccines for other
poxviruses.
Competitive Advantages:
<bullet> A Mpox nanoparticle vaccine may have fewer side effects
than available MVA based vaccines.
<bullet> The storage and transport requirements of a Mpox
nanoparticle vaccine are better suited to low resource settings than
MVA vaccines.
Inventors: Bernard Moss, MD, Ph.D.
Publications: Publication pending.
Intellectual Property: HHS Reference No. E-183-2022; U.S.
Provisional Application No. 63/402,702.
Licensing Contact: To license this technology, please contact
Benjamin Hurley at 240-669-5092 or <a href="/cdn-cgi/l/email-protection#2042454e4a414d494e0e4855524c4559604e49480e474f56"><span class="__cf_email__" data-cfemail="fc9e9992969d919592d294898e909985bc929594d29b938a">[email protected]</span></a>, and
reference E-183-2022.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this invention. For collaboration
opportunities, please contact Benjamin Hurley; 240-669-5092,
<a href="/cdn-cgi/l/email-protection#e78582898d868a8e89c98f92958b829ea7898e8fc9808891"><span class="__cf_email__" data-cfemail="f290979c98939f9b9cdc9a87809e978bb29c9b9adc959d84">[email protected]</span></a>.
Dated: May 9, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-10485 Filed 5-16-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 17, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.